Nocebo vs. Placebo: The challenges of trial design in analgesia research

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 2, 2015, Pages 143-150

  Vase, L ^a   Amanzio, M ^b   Price, D D ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; EMLA; LIDOCAINE; MISCELLANEOUS DRUGS AND AGENTS; NOCEBO; PLACEBO; REMIFENTANIL; RIZATRIPTAN; UNCLASSIFIED DRUG;

ANALGESIA; ARTICLE; CLINICAL TRIAL (TOPIC); EMOTION; HUMAN; MIGRAINE; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; DOCTOR PATIENT RELATION; NOCEBO EFFECT; PLACEBO EFFECT; PROCEDURES; PSYCHOLOGY; SUGGESTION;

HUMANS; NOCEBO EFFECT; PHYSICIAN-PATIENT RELATIONS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUGGESTION;

EID: 84927172947     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.31     Document Type: Article

References (74)

1. Enck, P., Bingel, U., Schedlowski, M. & Rief, W. The placebo response in medicine: minimize, maximize or personalize? Nat. Rev. Drug Discov. 12, 191-204 (2013).
2. Weimer, K. & Enck, P. Traditional and innovative experimental and clinical trial designs and their advantages and pitfalls. In Placebo (eds. Benedetti, F., Enck, P., Frisaldi, E. & Schedlowski, M.) 237272 (Springer, Berlin, 2014).
3. Dworkin, R.H. et al. Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 153, 1148-1158 (2012).
4. Baron, R. Oral presentation at Montreal. (2008).
5. Hauser, W., Bertram-Wunn, E., Bartram, C., Reinecke, H. & Tolle, T. Systematic review: placebo response in drug trials of fibromyalgia syndrome and painful peripheral diabetic neuropathy-magnitude and patient-related predictors. Pain 152, 1709-1717 (2011).
6. Pitz, M., Cheang, M. & Bernstein, C.N. Defining the predictors of the placebo response in irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 3, 237-247 (2005).
7. Silberman, S. Placebos are getting more effective. Drugmakers are desperate to know why. Wired Magazine, 2009.
8. Walsh, B.T., Seidman, S.N., Sysko, R. & Gould, M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA 287, 1840-1847 (2002).
9. Gewandter, J.S. et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain 155,1683-1695 (2014).
10. Simpson, D.M. et al. A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neupathic pain associated with human immunodeficiency virus neuropathy. Pain 155,1943-1954 (2014).
11. Vase, L., Riley, J.L. III. & Price, D.D. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain 99, 443-452 (2002).
12. Petersen, G. et al. The magnitude of nocebo effects in relation to pain: a meta-analysis. Pain 155,1426-1434 (2014).
13. Vase, L., Petersen, G.L., Riley, J.L. III. & Price, D.D. Factors contributing to large analgesic effects in placebo mechanism studies conducted between 2002 and 2007. Pain 145, 36-44 (2009).
14. Finnerup, N.B., Sindrup, S.H. & Jensen, T.S. The evidence for pharmacological treatment of neuropathic pain. Pain 150, 573-581 (2010).
15. Aslaksen, P.M., Bystad, M., Vambheim, S.M. & Flaten, M.A. Gender differences in placebo analgesia: event-related potentials and emotional modulation. Psychosom. Med. 73,193-199 (2011).
16. Daragh, M., Booth, R.J. & Consedine, N.S. Who responds to placebos? Considering the "placebo personality" via a transactional model. Psychol. Health Med. (2014) (doi: 10.1080/13548506.2014.936885).
17. Yu, R., Gollub, R.L., Vangel, M., Kaptchuk, T., Smoller, J.W. & Kong, J. Placebo analgesia and reward processing: integrating genetics, personality, and intrinsic brain activity. Hum. Brain Mapp. 35, 45834593 (2014).
18. Pecina, M., Martinez-Jauand, M., Hodgkinson, C., Stohler, C.S., Goldman, D. & Zubieta, J.K. FAAH selectively influences placebo effects. Mol. Psychiatry19, 385-391 (2014).
19. Cepeda, M.S., Berlin, J.A., Gao, C.Y., Wiegand, F. & Wada, D.R. Placebo response changes depending on the neuropathic pain syndrome: results of a systematic review and meta-analysis. Pain Med. 13, 575-595 (2012).
20. Colloca, L., Flaten, M. & Meissner, K. Placebo and Pain. From Bench to Bedside (Elsevier Academic Press, Amsterdam, 2013).
21. Byington, R.P., Curb, J.D. & Mattson, M.E. Assessment of double-blindness at the conclusion of the p-blocker heart attack trial. JAMA 253, 1733-1736 (1985).
22. Rabkin, J.G. et al. How blind is blind? Assessment of patient and doctor medication guesses in a placebo-controlled trial of imipramine and phenelzine. Psychiatry Res. 19, 75-86 (1986).
23. Margraf, J. et al. How "blind" are double-blind studies? J. Consult. Clin. Psychol. 59, 184-187 (1991).
24. Shah, E., Triantafyllou, K., Hana, A.A. & Pimental, M. Adverse events appear to unblind clinical trials in irritable bowel syndrome. Neurogas-troenterol. Motil. 26, 482-488 (2014).
25. Benedetti, F. Placebo Effects. Understanding the Mechanisms of Health and Disease (Oxford University Press, Oxford, 2009).
26. Walach, H. Placebo controls: historical, methodological and general aspects. Philos. Trans. R. Soc. B 366, 1870-1878 (2011).
27. Hoffman, G.A., Harrington, A. & Fields, H.L. Pain and the placebo: what we have learned. Perspect. Biol. Med. 48, 248-265 (2005).
28. Vase, L., Price, D.D., Verne, G.N. & Robinson, M.E. The contribution of changes in expected pain levels and desire for pain relief to placebo analgesia. In Psychological Methods of Pain Control: Basic Science and Clinical Perspectives (eds. Price, D.D. & Bushnell, M.C.) 207-234 (IAPS Press, Seattle, 2004).
29. Price, D.D., Finniss, D.G. & Benedetti, F. A comprehensive review of the placebo effect: recent advances and current thought. Annu. Rev. Psychol. 59, 565-590 (2008).
30. Moerman, D.E. & Jonas, W.B. Deconstructing the placebo effect and finding the meaning response. Ann. Intern. Med. 136, 471-476 (2002).
31. Kennedy, W.P. The nocebo reaction. Med. World 95, 203-205 (1961).
32. Hahn, R.A. The nocebo phenomenon, concept, evidence, and implications for public health. Prev. Med. 26, 207-611 (1997).
33. Amanzio, M., Corazzini, L.L., Vase, L. & Benedetti, F. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146, 261-269 (2009).
34. Mitsikostas, D.D., Mantonakis, L. & Chalarakis, N. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia 31, 550-561 (2011).
35. Amanzio, M., Pollo, A., Maggi, G. & Benedetti, F. Response variability to analgesics: a role for non-specific activation of endogenous opioids. Pain 90, 205-215 (2001).
36. Vase, L., Robinson, M.E., Verne, G.N. & Price, D.D. The contributions of suggestion, desire, and expectation to placebo effects in irritable bowel syndrome patients. An empirical investigation. Pain 105,17-25 (2003).
37. Vase, L., Robinson, M.E., Verne, G.N. & Price, D.D. Increased placebo analgesia overtime in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 115, 338-347 (2005).
38. Vase, L., Nørskov, K., Petersen, G.L. & Price, D.D. Patients' direct experiences as central elements of placebo analgesia. Philos. Trans. R. Soc. B 366,1913-1921 (2011).
39. Bingel, U. et al. The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil. Sci. Transl. Med. 3, 70ra14 (2011).
40. Lund, K., Vase, L., Petersen, G.L., Jensen, T.S. & Finnerup, N.B. Randomised controlled trials may underestimate drug effects: balanced placebo trial design. PLoS One 9, e84104 (2014).
41. Kam-Hansen, S. et al. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci. Transl. Med. 6, 218ra5 (2014).
42. Schenk, L.A., Sprenger, C., Geuter, S. & Buchel, C. Expectation requires treatment to boost pain relief: an fMRI study. Pain 155, 150-157 (2014).
43. Elsenbruch, S. How positive and negative expectations shape the experience of visceral pain. In Placebo (eds. Benedetti, F., Enck, P., Frisaldi, E. & Schedlowski, M.) 97-119 (Springer, Berlin, 2014).
44. Pollo, A., Amanzio, M., Arslanian, A., Casadio, C., Maggi, G. & Benedetti, F. Response expectancies in placebo analgesia and their clinical relevance. Pain 93, 77-84 (2001).
45. Verne, G.N., Robinson, M.E., Vase, L. & Price, D.D. Reversal of visceral and cutaneous hyperalgesia by local rectal anesthesia in irritable bowel syndrome (IBS) patients. Pain 105, 223-230 (2003).
46. Elsenbruch, S. et al. Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: an fMRI study in healthy placebo responders and nonresponders. Pain 153, 382-390 (2012).
47. Atlas, L.Y., Whittington, R.A., Lindquist, M.A., Wielgosz, J., Sonty, N. & Wager, R.D. Dissociable influences of opiates and expectations on pain. J. Neurosci. 32, 8053-8064 (2012).
48. Khan, S., Detke, M., Khan, S.R. & Mallinkrodt, C. Placebo response and antidepressant clinical trial outcome. J. Nerv. Ment. Dis. 191, 211-218 (2003).
49. Montgomery, G.H. & Kirsch, I. Classical conditioning and the placebo effect. Pain 72, 107-113 (1997).
50. Katz, J., Finnerup, N.B. & Dworkin, R.H. Clinical trial outcome in neuropathic pain: relationship to study characteristics. Neurology 70, 263-272 (2008).
51. Lee, S., Walker, J.R., Jakul, L. & Sexton, K. Does elimination of placebo responders in a placebo run-in increase the treatment effect in randomized clinical trials? A meta-analytic evaluation. Depress. Anxiety 19, 10-19 (2004).
52. Trivedi, M.H. & Rush, H. Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsycho-pharmacology 11, 33-43 (1994).
53. Colloca, L. & Finniss, D. Nocebo effects, patient-clinician communication, and therapeutic outcomes. JAMA 307, 567-568 (2012).
54. Gracely, R.H., Dubner, R., Deeter, W.R. & Wolskee, P.J. Clinicians' expectations influence placebo analgesia. Lancet 1, 43 (1985).
55. Amanzio, M. & Benedetti, F. Neuropharmacological dissection ofpla-cebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems. J. Neurosci. 19, 484-494 (1999).
56. Schmid, J. et al. Neural mechanisms mediating positive and negative treatment expectations in visceral pain: a functional magnetic resonance imaging study on placebo and nocebo effects in healthy volunteers. Pain 154, 2372-2380 (2013).
57. Price, D.D. & Barrell, J.J. Inner Experience and Neuroscience: Merging Both Perspectives (MIT Press, Cambridge, MA, 2012).
58. Petersen, G.L. et al. Expectations and positive emotional feelings accompany reductions in ongoing and evoked neuropathic pain following placebo interventions. Pain 2014 Oct 1. pii: S0304-3959(14)00459-X (doi: 10.1016lj.pain.2014.09.036 ).
59. De Pascalis, V., Chiaradia, C. & Carotenuto, E. The contribution of suggestibility and expectation to placebo analgesia phenomenon in an experimental setting. Pain 96, 393-402 (2002).
60. Price, D.D., Milling, L.S., Kirsch, I., Duff, A., Montgomery, G.H. & Nicholls, S.S. An analysis of factors that contribute to the magnitude of placebo analgesia in an experimental paradigm. Pain 83,147-156 (1999).
61. Price, D.D. & Barrell, J.J. Some general laws of human emotion: interrelationships between intensities of desire, expectation, and emotional feeling. J. Pers. 52, 389-409 (1984).
62. Scott, D.J., Stohler, C.S., Egnatuk, C.M., Wang, H., Koeppe, R.A. & Zubieta, J.K. Individual differences in reward responding explain placebo-induced expectations and effects. Neuron 55, 325-336 (2007).
63. Petersen, G.L. et al. Placebo manipulations reduce hyperalgesia in neuropathic pain. Pain 153,1292-1300 (2012).
64. Lyby, P.S., Aslaksen, P.M. & Flaten, M.A. Variability in placebo analgesia and the role of fear of pain - an ERP study. Pain 152, 2405-2412 (2011).
65. Lyby, P.S., Forsberg, J.T., Asli, O. & Flaten, M.A. Induced fear reduces the effectiveness of a placebo intervention on pain. Pain 153,1114-1121 (2012).
66. Elsenbruch, S., Schmid, J., Basler, M., Cesko, E., Schedlowski, M. & Benson, S. How positive and negative expectations shape the experience of visceral pain: an experimental pilot study in healthy women. J. Neurogastroenterol. Motil. 24, 914-e460 (2012) (doi:10.1111l j.1365-2982.2012.01950.x ).
67. Johansen, O., Brox, J. & Flaten, M.A. Placebo and nocebo responses, cortisol, and circulating beta-endorphin. Psychosom. Med. 65, 786-790 (2003).
68. Benedetti, F., Amanzio, M., Vighetti, S. & Asteggiano, G. The biochemical and neuroendocrine basis of the hyperalgesic nocebo effect. J. Neurosci. 26, 12014-12022 (2006).
69. Price, D.D., McGrath, P.A., Rafii, A. & Buckingham, B. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17, 45-56 (1983).
70. Price, D.D., Bush, F.M., Long, S. & Harkins, S.W. A comparison of pain measurement characteristics of mechanical visual analogue and simple numerical rating scales. Pain 56, 217-226 (1994).
71. Price, D.D., Barrell, J.E. & Barrell, J.J. A quantitative-experiential analysis of human emotions. Motiv. Emot. 9, 19-38 (1985).
72. Price, D.D., Riley, J. & Barrell, J.J. Are lived choices based on emotional processes? Cognit. Emot. 15, 365-379 (2001).
73. Staud, R. & Price, D.D. Importance of measuring placebo factors in complex clinical trials. Pain 138, 474 (2008).
74. Turner, J., Jensen, M., Warms, C. & Cardenas, D. Blinding effectiveness and association of pretreatment expectations with pain improvement in a double-blind randomized controlled trial. Pain 99, 91-99 (2002).